Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 26 | 4,932 | 48% |
| 2020 | 15 | 4,361 | 50% |
| 2021 | 23 | 4,474 | 52% |
| 2022 | 16 | 4,441 | 53% |
| 2023 | 20 | 4,847 | 55% |
| 2024 | 16 | 4,592 | 56% |
| 2025 from claims | – | 5,028 4,614–5,320 | 56% |
| 2026 forecast | – | 5,137 4,519–5,927 | 56% |
| 2027 forecast | – | 5,218 4,461–6,218 | 56% |
| 2028 forecast | – | 5,301 4,423–6,491 | 56% |
| 2029 forecast | – | 5,384 4,398–6,753 | 57% |
| 2030 forecast | – | 5,469 4,382–7,009 | 57% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 68% of the cases CMS names in California; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 99% inpatient hospital, 1% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 9 | 1,209−3.2%/yr | −3.2%/yr | 1.7 | 0% | 1,270 in 2030+0.9%/yr |
| Washington | 4 | 1,073−5.1%/yr | −5.1%/yr | 1.4 | 0% | 1,020 in 2030−0.9%/yr |
| Colorado | 2 | 764−2.7%/yr | −2.7%/yr | 1.6 | 0% | 860 in 2030+2.1%/yr |
| Oregon | 1 | 627−4.1%/yr | −4.1%/yr | 1.5 | 0% | 710 in 2030+2%/yr |
| Nevada | 3 | 409−3.9%/yr | −3.9%/yr | 1.5 | 0% | 440 in 2030+1.1%/yr |
| Utah | 1 | 352−0.3%/yr | −0.3%/yr | 1.6 | 0% | 360 in 2030+0.4%/yr |
| Montana | 2 | 340−0.4%/yr | −0.4%/yr | 1.8 | 0% | 360 in 2030+1%/yr |
| Idaho | 0 | 307−1.1%/yr | −1.1%/yr | 1.5 | 0% | 320 in 2030+0.6%/yr |
| New Mexico | 0 | 182−11%/yr | −11%/yr | 0.8 | 0% | 170 in 2030−1.5%/yr |
| Alaska | 0 | 161−1.8%/yr | −1.8%/yr | 1.3 | 0% | 170 in 2030+1.2%/yr |
| Wyoming | 0 | 105−1.1%/yr | −1.1%/yr | 1.0 | 0% | 110 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 233 | 17,286−1.1%/yr | −1.1%/yr | 5.50.8× | 15% | 19,300 in 2030+1.8%/yr |
| Cholecystectomy & appendectomy | 221 | 11,459−2.6%/yr | −2.6%/yr | 3.50.9× | 2% | 12,600 in 2030+1.6%/yr |
| Antireflux & hiatal hernia surgery | 37 | 2,040+1.2%/yr | +1.2%/yr | 0.60.8× | 0% | 2,990 in 2030+6.6%/yr |
| Breast reconstruction | 12 | 1,522−3.4%/yr | −3.4%/yr | 0.51.2× | 0% | 2,040 in 2030+5%/yr |
| Bariatric surgery | 3 | 481−12%/yr | −12%/yr | 0.10.8× | 0% | 400 in 2030−3.2%/yr |
Colorectal resection in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Intuitive Surgical leads with 69% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 4 companies reported engagement with California’s surgeons worth $1.4M in consulting, speaking, meals and travel tied to these products, about $90K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.